These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 34973501)
1. Effect of Donor Lymphocyte Infusion From Two Types of Donors on Mixed Chimerism With Secondary Graft Failure After Allogeneic Hematopoietic Stem Cell Transplantation. Ren RR; Ma LM; Xie YX; Tian WW; Wang T Transplant Cell Ther; 2022 Mar; 28(3):152.e1-152.e7. PubMed ID: 34973501 [TBL] [Abstract][Full Text] [Related]
2. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained. Caldemeyer LE; Akard LP; Edwards JR; Tandra A; Wagenknecht DR; Dugan MJ Biol Blood Marrow Transplant; 2017 Nov; 23(11):1989-1997. PubMed ID: 28712934 [TBL] [Abstract][Full Text] [Related]
3. Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases. Umeda K; Adachi S; Tanaka S; Miki M; Okada K; Hashii Y; Inoue M; Cho Y; Koh K; Goto H; Kajiwara R; Hyakuna N; Kato K; Morio T; Yabe H; Pediatr Blood Cancer; 2016 Dec; 63(12):2221-2229. PubMed ID: 27554591 [TBL] [Abstract][Full Text] [Related]
4. Repeated CD45RA-depleted DLI successfully increases donor chimerism in a patient with beta-thalassemia major after haploidentical stem cell transplant. Chan WYK; Kwok JSY; Chiang AKS; Chan GCF; Lee PPW; Ha SY; Cheuk DKL Pediatr Transplant; 2021 Aug; 25(5):e13945. PubMed ID: 33314508 [TBL] [Abstract][Full Text] [Related]
5. Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. Kako S; Yamazaki H; Ohashi K; Ozawa Y; Ota S; Kanda Y; Maeda T; Kato J; Ishiyama K; Matsuoka KI; Miyamoto T; Iida H; Ikegame K; Fukuda T; Ichinohe T; Atsuta Y; Mori T; Biol Blood Marrow Transplant; 2020 Mar; 26(3):445-450. PubMed ID: 31618688 [TBL] [Abstract][Full Text] [Related]
6. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion. Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743 [TBL] [Abstract][Full Text] [Related]
7. Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter. Ros-Soto J; Snowden JA; Szydlo R; Nicholson E; Madrigal A; Easdale S; Potter M; Ethell M; Anthias C Transplant Cell Ther; 2022 Apr; 28(4):183.e1-183.e8. PubMed ID: 35104660 [TBL] [Abstract][Full Text] [Related]
8. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions. Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747 [TBL] [Abstract][Full Text] [Related]
9. [Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation]. Slesarchuk OA; Babenko EV; Semenova EV; Bondarenko SN; Éstrina MA; Morozova EV; Paina OV; Vavilov VN; Smirnov BI; Zubarovskaia LS; Afanas'ev BV Ter Arkh; 2013; 85(7):26-33. PubMed ID: 24137944 [TBL] [Abstract][Full Text] [Related]
10. Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes. Llaurador G; Nicoletti E; Prockop SE; Hsu S; Fuller K; Mauguen A; O'Reilly RJ; Boelens JJ; Boulad F Transplant Cell Ther; 2021 Sep; 27(9):780.e1-780.e14. PubMed ID: 34082161 [TBL] [Abstract][Full Text] [Related]
11. Mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia. Zhang Y; Li Y; Wu L; Zhou M; Wang C; Mo W; Chen X; Xu S; Zhou R; Wang S; Zhang Y Hematology; 2021 Dec; 26(1):435-443. PubMed ID: 34130602 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Haines HL; Bleesing JJ; Davies SM; Hornung L; Jordan MB; Marsh RA; Filipovich AH Biol Blood Marrow Transplant; 2015 Feb; 21(2):288-92. PubMed ID: 25464116 [TBL] [Abstract][Full Text] [Related]
13. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study. Rampotas A; Sockel K; Panitsas F; Theuser C; Bornhauser M; Hernani R; Hernandez-Boluda JC; Esquirol A; Avenoso D; Tsirigotis P; Robin M; Czerw T; Helbig G; Roddie C; Lambert J; McLornan DP Transplant Cell Ther; 2023 Nov; 29(11):687.e1-687.e7. PubMed ID: 37633414 [TBL] [Abstract][Full Text] [Related]
14. Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Bar M; Flowers MED; Storer BE; Chauncey TR; Pulsipher MA; Thakar MS; Bethge W; Storb R; Maloney DG; Sandmaier BM Biol Blood Marrow Transplant; 2018 Feb; 24(2):308-313. PubMed ID: 29032276 [TBL] [Abstract][Full Text] [Related]
15. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation. Karasu GT; Yesilipek MA; Karauzum SB; Uygun V; Manguoglu E; Kupesiz A; Hazar V Pediatr Blood Cancer; 2012 Mar; 58(3):453-8. PubMed ID: 21990066 [TBL] [Abstract][Full Text] [Related]
16. Cytokine expression in tumors treated with donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. Conrad R; Remberger M; Cederlund K; Barkholt L Immunotherapy; 2011 Mar; 3(3):443-51. PubMed ID: 21395385 [TBL] [Abstract][Full Text] [Related]
17. Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion-dependent pediatric thalassemia patients. Chen H; Li XY; Zhan LP; Fang JP; Huang K; Li Y; Weng WJ; Xu LH; Xu HG; Zhou DH Pediatr Transplant; 2020 Dec; 24(8):e13876. PubMed ID: 33098346 [TBL] [Abstract][Full Text] [Related]
18. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882 [TBL] [Abstract][Full Text] [Related]
19. Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation. Harada K Int J Hematol; 2023 Aug; 118(2):158-168. PubMed ID: 37014602 [TBL] [Abstract][Full Text] [Related]
20. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]